As CEA is expressed by many different kinds of cancers, MEDI-565 may be applicable to a wide range of adenocarcinoma as a novel treatment with the potential for high efficacy and less toxicity than conventional therapies. Here, CEACAM5 is linked to adenocarcinoma.